Agenda
Applications for consideration at this meeting
- 1357.1 F-18 Fluorodeoxyglucose (FDG) positron emission tomography (PET) for the evaluation of breast cancer
- 1405.1 MBS Item for Pulmonary Rehabilitation (Re-submission)
- 1407 EGFR mutation testing to determine eligibility for access to PBS subsidised AZD9291 second line therapy in patients with locally advanced or metastatic NSCLC
- 1455 Proton Beam Therapy for patients supported under the Medical Treatment Overseas Program
- 1456 17p Deletion Testing for Access to Venetoclax in Patients with Relapsed/Refractory Chronic Lymphoid Leukaemia
- 1466 Vertebroplasty for severely painful osteoporotic vertebral fractures of less than 6 weeks duration
- 1498 Serum soluble transferrin receptor
- 1510 Emicizumab for routine prophylaxis to prevent bleeding or reduce the frequency of bleeding episodes in patients with Haemophilia A (congenital Factor VIII deficiency) with Factor VIII inhibitors
- 1519 Tisagenlecleucel (CTL019) for treatment of refractory CD19-positive leukaemia and lymphoma
- 1530 Purified human alpha1-proteinase inhibitor (A1-PI) for the treatment of alpha1-proteinase inhibitor deficiency, leading to chronic obstructive pulmonary disease (COPD)
- 1541 Micro-bypass glaucoma surgery (MBGS) device implantation as a standalone procedure in patients with open-angle glaucoma (OAG)
- 1543 Request to amend Medicare Benefits Schedule (MBS) item 73336 (BRAF mutation test for treatment of metastatic melanoma) to include reference to encorafenib
Related information
Committee: